These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15452226)

  • 21. Human rhinovirus 14 complexed with fragments of active antiviral compounds.
    Bibler-Muckelbauer JK; Kremer MJ; Rossmann MG; Diana GD; Dutko FJ; Pevear DC; McKinlay MA
    Virology; 1994 Jul; 202(1):360-9. PubMed ID: 8009848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural studies on human rhinovirus 14 drug-resistant compensation mutants.
    Hadfield AT; Oliveira MA; Kim KH; Minor I; Kremer MJ; Heinz BA; Shepard D; Pevear DC; Rueckert RR; Rossmann MG
    J Mol Biol; 1995 Oct; 253(1):61-73. PubMed ID: 7473717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular mechanism of a specific capsid binder resistance caused by mutations outside the binding pocket.
    Braun H; Kirchmair J; Williamson MJ; Makarov VA; Riabova OB; Glen RC; Sauerbrei A; Schmidtke M
    Antiviral Res; 2015 Nov; 123():138-45. PubMed ID: 26391975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C.
    Mello C; Aguayo E; Rodriguez M; Lee G; Jordan R; Cihlar T; Birkus G
    Antimicrob Agents Chemother; 2014; 58(3):1546-55. PubMed ID: 24366736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Syncytial Virus and Other Respiratory Viruses.
    Ohol YM; Wang Z; Kemble G; Duke G
    PLoS One; 2015; 10(12):e0144648. PubMed ID: 26659560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory effect of dibenzofuran and dibenzosuberol derivatives on rhinovirus replication in vitro; effective prevention of viral entry by dibenzosuberenone.
    Murray MA; Babe LM
    Antiviral Res; 1999 Dec; 44(2):123-31. PubMed ID: 10669262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment.
    Schmidtke M; Hammerschmidt E; Schüler S; Zell R; Birch-Hirschfeld E; Makarov VA; Riabova OB; Wutzler P
    J Antimicrob Chemother; 2005 Oct; 56(4):648-56. PubMed ID: 16150864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human rhinovirus type 16: mutant V1210A requires capsid-binding drug for assembly of pentamers to form virions during morphogenesis.
    Lee WM; Wang W
    J Virol; 2003 Jun; 77(11):6235-44. PubMed ID: 12743280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular dynamics investigation of the effect of an antiviral compound on human rhinovirus.
    Phelps DK; Post CB
    Protein Sci; 1999 Nov; 8(11):2281-9. PubMed ID: 10595531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides.
    Ninomiya Y; Shimma N; Ishitsuka H
    Antiviral Res; 1990 Feb; 13(2):61-74. PubMed ID: 2160796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VP4 protein from human rhinovirus 14 is released by pressure and locked in the capsid by the antiviral compound WIN.
    Gonçalves RB; Mendes YS; Soares MR; Katpally U; Smith TJ; Silva JL; Oliveira AC
    J Mol Biol; 2007 Feb; 366(1):295-306. PubMed ID: 17161425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses.
    Lacroix C; Laconi S; Angius F; Coluccia A; Silvestri R; Pompei R; Neyts J; Leyssen P
    Virol J; 2015 Jul; 12():106. PubMed ID: 26169596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pleconaril: a novel antipicornaviral drug.
    Romero JR
    Expert Opin Investig Drugs; 2001 Feb; 10(2):369-79. PubMed ID: 11178348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pocket factors are unlikely to play a major role in the life cycle of human rhinovirus.
    Katpally U; Smith TJ
    J Virol; 2007 Jun; 81(12):6307-15. PubMed ID: 17428846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural analysis of a series of antiviral agents complexed with human rhinovirus 14.
    Badger J; Minor I; Kremer MJ; Oliveira MA; Smith TJ; Griffith JP; Guerin DM; Krishnaswamy S; Luo M; Rossmann MG
    Proc Natl Acad Sci U S A; 1988 May; 85(10):3304-8. PubMed ID: 2835768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New class of early-stage enterovirus inhibitors with a novel mechanism of action.
    Ma Y; Abdelnabi R; Delang L; Froeyen M; Luyten W; Neyts J; Mirabelli C
    Antiviral Res; 2017 Nov; 147():67-74. PubMed ID: 28993161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CoMFA analysis of the interactions of antipicornavirus compounds in the binding pocket of human rhinovirus-14.
    Diana GD; Kowalczyk P; Treasurywala AM; Oglesby RC; Pevear DC; Dutko FJ
    J Med Chem; 1992 Mar; 35(6):1002-8. PubMed ID: 1313108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular dynamics simulations of human rhinovirus and an antiviral compound.
    Speelman B; Brooks BR; Post CB
    Biophys J; 2001 Jan; 80(1):121-9. PubMed ID: 11159387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A synthetic STING agonist inhibits the replication of human parainfluenza virus 3 and rhinovirus 16 through distinct mechanisms.
    Zhu Q; Hu H; Liu H; Shen H; Yan Z; Gao L
    Antiviral Res; 2020 Nov; 183():104933. PubMed ID: 32949635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14.
    Shepard DA; Heinz BA; Rueckert RR
    J Virol; 1993 Apr; 67(4):2245-54. PubMed ID: 8383239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.